Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:15 pm
| PEG Ratio | -4.06 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dev Labtech Venture Ltd reported a total revenue of ₹30.34 Cr for the financial year ending March 2023, reflecting a steady increase from ₹26.98 Cr in the previous fiscal year. The company’s revenue continued to grow, reaching ₹43.22 Cr in March 2024 and further escalating to ₹52.41 Cr for the financial year 2025. The quarterly sales figures indicate a robust upward trajectory, with sales rising from ₹19.43 Cr in March 2022 to ₹20.68 Cr in March 2023, and subsequently to ₹22.30 Cr in March 2024. This trend signifies a strong recovery and growth in business operations. However, the company faced fluctuations in its quarterly performance, particularly a dip in operating profit margins, which recorded a high of 10.56% in September 2022 before settling at 5.68% by March 2025. Overall, the revenue growth trajectory positions the company favorably within its sector, despite the volatility in profitability margins.
Profitability and Efficiency Metrics
Dev Labtech’s profitability metrics reflect a mixed performance. The operating profit margin (OPM) stood at a low of 1.97% for the year ending March 2025, down from a peak of 10.56% in September 2022. This decline in efficiency is concerning, given that the average OPM in the industry typically hovers around 5-15%. The net profit for March 2025 was ₹1.29 Cr, which indicates a decline compared to ₹1.34 Cr in the previous year, with the net profit margin dropping to 2.46%. The interest coverage ratio of 25.49x for the latest reporting period suggests that the company can comfortably cover its interest obligations, highlighting a strength in financial management. However, the cash conversion cycle (CCC) has dramatically increased to 313.45 days, indicating potential inefficiencies in working capital management, which could hinder operational responsiveness and liquidity.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dev Labtech Venture Ltd reflects a solid foundation, with total assets reported at ₹49.12 Cr as of September 2025. The company maintains a low level of borrowings, which stood at ₹1.07 Cr, resulting in a debt-to-equity ratio of merely 0.02, indicating minimal financial leverage and a strong equity base. Reserves have significantly increased to ₹32.25 Cr, providing a cushion for future investments or operational challenges. The return on equity (ROE) is relatively low at 3.85%, which is below typical industry standards, suggesting that the company may not be fully utilizing its equity base to generate profits. The price-to-book value ratio of 1.63x suggests that the stock is trading at a premium compared to its book value, reflecting investor optimism about future growth potential despite current profitability challenges.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dev Labtech Venture Ltd indicates a significant presence of promoter holdings, which stood at 56.69% as of September 2025. This level of promoter confidence can be a positive signal to investors, as it suggests alignment of interests between management and shareholders. The public holding is reported at 43.31%, which reflects a healthy distribution of shares among retail investors. However, the reduction in promoter holding from 68.01% in March 2023 to the current level raises questions about potential dilution of control or strategic shifts within the company. The number of shareholders has increased to 955, illustrating growing interest and confidence among investors, despite the mixed performance in profitability metrics. This evolving shareholding structure may impact future governance and strategic decisions within the company.
Outlook, Risks, and Final Insight
The outlook for Dev Labtech Venture Ltd appears cautiously optimistic, given the company’s revenue growth trajectory and strong balance sheet. However, challenges persist with declining profitability margins and an exceedingly high cash conversion cycle, which pose significant operational risks. The company needs to focus on improving efficiency in its working capital management to enhance profitability. Furthermore, while the low levels of debt provide financial flexibility, the low ROE suggests that management must work on strategies to better leverage equity for growth. A potential positive scenario could emerge if the company manages to streamline operations and improve margins, while a negative scenario could unfold if operational inefficiencies persist, impacting cash flows and investor sentiment. Addressing these aspects will be crucial for sustaining growth and enhancing shareholder value in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 107 Cr. | 27.9 | 625/20.5 | 1.05 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 3,065 Cr. | 190 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 46.2 Cr. | 3.62 | 7.43/2.70 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,278.29 Cr | 222.79 | 277.09 | 219.28 | 0.25% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19.43 | 9.66 | 20.68 | 20.92 | 22.30 | 19.51 | 32.90 | 49.24 |
| Expenses | 18.99 | 8.64 | 19.80 | 18.82 | 21.53 | 18.30 | 31.03 | 48.27 |
| Operating Profit | 0.44 | 1.02 | 0.88 | 2.10 | 0.77 | 1.21 | 1.87 | 0.97 |
| OPM % | 2.26% | 10.56% | 4.26% | 10.04% | 3.45% | 6.20% | 5.68% | 1.97% |
| Other Income | 0.11 | 0.16 | -0.00 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| Interest | 0.06 | 0.05 | 0.05 | 0.07 | 0.05 | 0.05 | 0.07 | 0.04 |
| Depreciation | 0.04 | 0.27 | 0.29 | 0.46 | 0.47 | 0.50 | 0.61 | 0.56 |
| Profit before tax | 0.45 | 0.86 | 0.54 | 1.58 | 0.25 | 0.66 | 1.19 | 0.37 |
| Tax % | 15.56% | 34.88% | 18.52% | 17.09% | 88.00% | 25.76% | 31.93% | 5.41% |
| Net Profit | 0.37 | 0.57 | 0.45 | 1.31 | 0.03 | 0.48 | 0.81 | 0.34 |
| EPS in Rs | 2.94 | 1.17 | 0.54 | 1.58 | 0.04 | 0.46 | 0.72 | 0.29 |
Last Updated: February 2, 2026, 8:16 am
Below is a detailed analysis of the quarterly data for Dev Labtech Venture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 49.24 Cr.. The value appears strong and on an upward trend. It has increased from 32.90 Cr. (Mar 2025) to 49.24 Cr., marking an increase of 16.34 Cr..
- For Expenses, as of Sep 2025, the value is 48.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.03 Cr. (Mar 2025) to 48.27 Cr., marking an increase of 17.24 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.97 Cr.. The value appears to be declining and may need further review. It has decreased from 1.87 Cr. (Mar 2025) to 0.97 Cr., marking a decrease of 0.90 Cr..
- For OPM %, as of Sep 2025, the value is 1.97%. The value appears to be declining and may need further review. It has decreased from 5.68% (Mar 2025) to 1.97%, marking a decrease of 3.71%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
- For Depreciation, as of Sep 2025, the value is 0.56 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.61 Cr. (Mar 2025) to 0.56 Cr., marking a decrease of 0.05 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.37 Cr.. The value appears to be declining and may need further review. It has decreased from 1.19 Cr. (Mar 2025) to 0.37 Cr., marking a decrease of 0.82 Cr..
- For Tax %, as of Sep 2025, the value is 5.41%. The value appears to be improving (decreasing) as expected. It has decreased from 31.93% (Mar 2025) to 5.41%, marking a decrease of 26.52%.
- For Net Profit, as of Sep 2025, the value is 0.34 Cr.. The value appears to be declining and may need further review. It has decreased from 0.81 Cr. (Mar 2025) to 0.34 Cr., marking a decrease of 0.47 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.29. The value appears to be declining and may need further review. It has decreased from 0.72 (Mar 2025) to 0.29, marking a decrease of 0.43.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:52 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 11.79 | 12.24 | 26.98 | 30.34 | 43.22 | 52.41 | 82.14 |
| Expenses | 11.41 | 11.96 | 26.28 | 28.43 | 40.35 | 49.33 | 79.30 |
| Operating Profit | 0.38 | 0.28 | 0.70 | 1.91 | 2.87 | 3.08 | 2.84 |
| OPM % | 3.22% | 2.29% | 2.59% | 6.30% | 6.64% | 5.88% | 3.46% |
| Other Income | 0.00 | 0.04 | 0.12 | 0.16 | 0.01 | 0.00 | 0.00 |
| Interest | 0.18 | 0.16 | 0.14 | 0.10 | 0.12 | 0.12 | 0.11 |
| Depreciation | 0.15 | 0.11 | 0.09 | 0.55 | 0.93 | 1.11 | 1.17 |
| Profit before tax | 0.05 | 0.05 | 0.59 | 1.42 | 1.83 | 1.85 | 1.56 |
| Tax % | 100.00% | 40.00% | 16.95% | 27.46% | 26.78% | 29.73% | |
| Net Profit | 0.00 | 0.04 | 0.49 | 1.02 | 1.34 | 1.29 | 1.15 |
| EPS in Rs | 0.00 | 1.91 | 3.90 | 1.23 | 1.62 | 1.14 | 1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1125.00% | 108.16% | 31.37% | -3.73% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1016.84% | -76.79% | -35.10% |
Dev Labtech Venture Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 25% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:44 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.21 | 0.21 | 1.26 | 8.27 | 8.27 | 11.30 | 11.86 |
| Reserves | 1.24 | 1.28 | 0.77 | 10.61 | 17.51 | 29.87 | 32.25 |
| Borrowings | 1.54 | 1.78 | 1.23 | 1.13 | 1.10 | 1.07 | 1.07 |
| Other Liabilities | 4.13 | 3.87 | 5.68 | 3.72 | 1.79 | 1.53 | 3.94 |
| Total Liabilities | 7.12 | 7.14 | 8.94 | 23.73 | 28.67 | 43.77 | 49.12 |
| Fixed Assets | 0.81 | 0.71 | 0.37 | 4.15 | 5.01 | 4.89 | 4.36 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Other Assets | 6.31 | 6.43 | 8.57 | 19.58 | 23.66 | 38.88 | 44.75 |
| Total Assets | 7.12 | 7.14 | 8.94 | 23.73 | 28.67 | 43.77 | 49.12 |
Below is a detailed analysis of the balance sheet data for Dev Labtech Venture Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.86 Cr.. The value appears strong and on an upward trend. It has increased from 11.30 Cr. (Mar 2025) to 11.86 Cr., marking an increase of 0.56 Cr..
- For Reserves, as of Sep 2025, the value is 32.25 Cr.. The value appears strong and on an upward trend. It has increased from 29.87 Cr. (Mar 2025) to 32.25 Cr., marking an increase of 2.38 Cr..
- For Borrowings, as of Sep 2025, the value is 1.07 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 1.07 Cr..
- For Other Liabilities, as of Sep 2025, the value is 3.94 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.53 Cr. (Mar 2025) to 3.94 Cr., marking an increase of 2.41 Cr..
- For Total Liabilities, as of Sep 2025, the value is 49.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.77 Cr. (Mar 2025) to 49.12 Cr., marking an increase of 5.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4.36 Cr.. The value appears to be declining and may need further review. It has decreased from 4.89 Cr. (Mar 2025) to 4.36 Cr., marking a decrease of 0.53 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.01 Cr., marking an increase of 0.01 Cr..
- For Other Assets, as of Sep 2025, the value is 44.75 Cr.. The value appears strong and on an upward trend. It has increased from 38.88 Cr. (Mar 2025) to 44.75 Cr., marking an increase of 5.87 Cr..
- For Total Assets, as of Sep 2025, the value is 49.12 Cr.. The value appears strong and on an upward trend. It has increased from 43.77 Cr. (Mar 2025) to 49.12 Cr., marking an increase of 5.35 Cr..
Notably, the Reserves (32.25 Cr.) exceed the Borrowings (1.07 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -1.16 | -1.50 | -0.53 | 0.78 | 1.77 | 2.01 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 70.28 | 89.16 | 55.20 | 56.54 | 16.13 | 33.43 |
| Inventory Days | 191.01 | 123.38 | 48.27 | 122.84 | 208.18 | 285.06 |
| Days Payable | 192.65 | 160.22 | 85.88 | 33.95 | 5.37 | 5.04 |
| Cash Conversion Cycle | 68.63 | 52.32 | 17.58 | 145.43 | 218.94 | 313.45 |
| Working Capital Days | 46.44 | 56.36 | 33.28 | 119.58 | 183.94 | 261.02 |
| ROCE % | 6.71% | 18.99% | 11.69% | 8.32% | 5.70% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.31 | 1.62 | 0.96 | 3.47 | 1.74 |
| Diluted EPS (Rs.) | 1.09 | 1.62 | 0.96 | 3.47 | 1.74 |
| Cash EPS (Rs.) | 2.13 | 2.75 | 1.90 | 4.16 | 6.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.42 | 31.16 | 22.83 | 15.28 | 70.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.42 | 31.16 | 22.83 | 15.28 | 70.86 |
| Revenue From Operations / Share (Rs.) | 46.37 | 52.26 | 36.68 | 213.58 | 584.18 |
| PBDIT / Share (Rs.) | 2.72 | 3.48 | 2.31 | 5.42 | 15.30 |
| PBIT / Share (Rs.) | 1.74 | 2.36 | 1.64 | 4.74 | 10.20 |
| PBT / Share (Rs.) | 1.63 | 2.21 | 1.70 | 3.63 | 2.61 |
| Net Profit / Share (Rs.) | 1.14 | 1.62 | 1.23 | 3.47 | 1.74 |
| PBDIT Margin (%) | 5.86 | 6.66 | 6.29 | 2.53 | 2.61 |
| PBIT Margin (%) | 3.75 | 4.50 | 4.46 | 2.21 | 1.74 |
| PBT Margin (%) | 3.52 | 4.23 | 4.64 | 1.69 | 0.44 |
| Net Profit Margin (%) | 2.46 | 3.10 | 3.35 | 1.62 | 0.29 |
| Return on Networth / Equity (%) | 3.14 | 5.20 | 5.39 | 22.71 | 2.45 |
| Return on Capital Employeed (%) | 4.63 | 7.22 | 6.77 | 19.08 | 7.35 |
| Return On Assets (%) | 2.95 | 4.67 | 4.29 | 4.91 | 0.51 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.05 | 0.59 | 0.93 |
| Total Debt / Equity (X) | 0.02 | 0.04 | 0.05 | 0.63 | 1.20 |
| Asset Turnover Ratio (%) | 1.45 | 1.65 | 1.86 | 3.35 | 1.72 |
| Current Ratio (X) | 29.54 | 14.01 | 5.24 | 1.44 | 1.45 |
| Quick Ratio (X) | 5.02 | 2.28 | 3.18 | 0.90 | 0.77 |
| Inventory Turnover Ratio (X) | 2.01 | 0.16 | 0.83 | 8.34 | 1.03 |
| Interest Coverage Ratio (X) | 25.49 | 24.43 | 18.29 | 4.89 | 2.02 |
| Interest Coverage Ratio (Post Tax) (X) | 11.72 | 12.38 | 9.23 | 3.31 | 1.23 |
| Enterprise Value (Cr.) | 68.21 | 83.64 | 37.44 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.30 | 1.94 | 1.23 | 0.00 | 0.00 |
| EV / EBITDA (X) | 22.17 | 29.04 | 19.60 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.28 | 1.91 | 1.39 | 0.00 | 0.00 |
| Price / BV (X) | 1.63 | 3.21 | 2.23 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.28 | 1.91 | 1.39 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dev Labtech Venture Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 5. It has decreased from 1.62 (Mar 24) to 1.31, marking a decrease of 0.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 5. It has decreased from 1.62 (Mar 24) to 1.09, marking a decrease of 0.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 3. It has decreased from 2.75 (Mar 24) to 2.13, marking a decrease of 0.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.42. It has increased from 31.16 (Mar 24) to 36.42, marking an increase of 5.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.42. It has increased from 31.16 (Mar 24) to 36.42, marking an increase of 5.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 46.37. It has decreased from 52.26 (Mar 24) to 46.37, marking a decrease of 5.89.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 2.72, marking a decrease of 0.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.74. This value is within the healthy range. It has decreased from 2.36 (Mar 24) to 1.74, marking a decrease of 0.62.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.63, marking a decrease of 0.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 1.62 (Mar 24) to 1.14, marking a decrease of 0.48.
- For PBDIT Margin (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 10. It has decreased from 6.66 (Mar 24) to 5.86, marking a decrease of 0.80.
- For PBIT Margin (%), as of Mar 25, the value is 3.75. This value is below the healthy minimum of 10. It has decreased from 4.50 (Mar 24) to 3.75, marking a decrease of 0.75.
- For PBT Margin (%), as of Mar 25, the value is 3.52. This value is below the healthy minimum of 10. It has decreased from 4.23 (Mar 24) to 3.52, marking a decrease of 0.71.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 3.10 (Mar 24) to 2.46, marking a decrease of 0.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 15. It has decreased from 5.20 (Mar 24) to 3.14, marking a decrease of 2.06.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.63. This value is below the healthy minimum of 10. It has decreased from 7.22 (Mar 24) to 4.63, marking a decrease of 2.59.
- For Return On Assets (%), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 4.67 (Mar 24) to 2.95, marking a decrease of 1.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.45. It has decreased from 1.65 (Mar 24) to 1.45, marking a decrease of 0.20.
- For Current Ratio (X), as of Mar 25, the value is 29.54. This value exceeds the healthy maximum of 3. It has increased from 14.01 (Mar 24) to 29.54, marking an increase of 15.53.
- For Quick Ratio (X), as of Mar 25, the value is 5.02. This value exceeds the healthy maximum of 2. It has increased from 2.28 (Mar 24) to 5.02, marking an increase of 2.74.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.01. This value is below the healthy minimum of 4. It has increased from 0.16 (Mar 24) to 2.01, marking an increase of 1.85.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 25.49. This value is within the healthy range. It has increased from 24.43 (Mar 24) to 25.49, marking an increase of 1.06.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.72. This value is within the healthy range. It has decreased from 12.38 (Mar 24) to 11.72, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 68.21. It has decreased from 83.64 (Mar 24) to 68.21, marking a decrease of 15.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.94 (Mar 24) to 1.30, marking a decrease of 0.64.
- For EV / EBITDA (X), as of Mar 25, the value is 22.17. This value exceeds the healthy maximum of 15. It has decreased from 29.04 (Mar 24) to 22.17, marking a decrease of 6.87.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.28, marking a decrease of 0.63.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 3.21 (Mar 24) to 1.63, marking a decrease of 1.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.28, marking a decrease of 0.63.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dev Labtech Venture Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.63% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.14% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 96.2 (Industry average Stock P/E: 277.09)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Gems, Jewellery & Precious Metals | GF/22-23, Pattani Plaza, Bhavnagar Gujarat 364002 | info@devlabtechventure.com http://www.devlabtechventure.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jerambhai Lavjibhai Donda | Chairman & Managing Director |
| Mr. Jay Jerambhai Donda | WholeTime Director & CFO |
| Mrs. Dimple Jay Donda | Non Executive Director |
| Mr. Vivekbhai Tulsibhai Mavani | Ind. Non-Executive Director |
| Mr. Brijeshkumar Maheshbhai Pathak | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Dev Labtech Venture Ltd?
Dev Labtech Venture Ltd's intrinsic value (as of 12 February 2026) is ₹85.81 which is 7.93% lower the current market price of ₹93.20, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹111 Cr. market cap, FY2025-2026 high/low of ₹105/52.0, reserves of ₹32.25 Cr, and liabilities of ₹49.12 Cr.
What is the Market Cap of Dev Labtech Venture Ltd?
The Market Cap of Dev Labtech Venture Ltd is 111 Cr..
What is the current Stock Price of Dev Labtech Venture Ltd as on 12 February 2026?
The current stock price of Dev Labtech Venture Ltd as on 12 February 2026 is ₹93.2.
What is the High / Low of Dev Labtech Venture Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dev Labtech Venture Ltd stocks is ₹105/52.0.
What is the Stock P/E of Dev Labtech Venture Ltd?
The Stock P/E of Dev Labtech Venture Ltd is 96.2.
What is the Book Value of Dev Labtech Venture Ltd?
The Book Value of Dev Labtech Venture Ltd is 37.2.
What is the Dividend Yield of Dev Labtech Venture Ltd?
The Dividend Yield of Dev Labtech Venture Ltd is 0.00 %.
What is the ROCE of Dev Labtech Venture Ltd?
The ROCE of Dev Labtech Venture Ltd is 5.70 %.
What is the ROE of Dev Labtech Venture Ltd?
The ROE of Dev Labtech Venture Ltd is 3.85 %.
What is the Face Value of Dev Labtech Venture Ltd?
The Face Value of Dev Labtech Venture Ltd is 10.0.